Allergy Therapeutics plc (LON:AGY – Get Free Report) hit a new 52-week low during trading on Tuesday . The stock traded as low as GBX 5 and last traded at GBX 5.17, with a volume of 525312 shares traded. The stock had previously closed at GBX 5.50.
Allergy Therapeutics Stock Performance
The company has a debt-to-equity ratio of 629.58, a current ratio of 1.13 and a quick ratio of 1.48. The company has a market capitalization of £331.82 million, a price-to-earnings ratio of -5.40, a price-to-earnings-growth ratio of -30.70 and a beta of 0.87. The business has a fifty day moving average price of GBX 6.70 and a 200 day moving average price of GBX 9.19.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Recommended Stories
- Five stocks we like better than Allergy Therapeutics
- Cleared for Takeoff: Archer Aviation Changes the Math on eVTOL
- Voyager Technologies: Space Force Deal Fuels Growth Despite Heavy Cash Burn
- Franco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care?
- GE Vernova’s AI Power Boom Faces a Profit Test
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
